Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Among authors: gutierrez m. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Free PMC article. Clinical Trial.
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
Puglisi M, Molife LR, de Jonge MJ, Khan KH, Doorn LV, Forster MD, Blanco M, Gutierrez M, Franklin C, Busman T, Yang J, Eskens FA. Puglisi M, et al. Among authors: gutierrez m. Future Oncol. 2021 Jul;17(21):2747-2758. doi: 10.2217/fon-2021-0140. Epub 2021 Apr 14. Future Oncol. 2021. PMID: 33849298 Free article. Clinical Trial.
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
Chénard-Poirier M, Hansen AR, Gutierrez ME, Rasco D, Xing Y, Chen LC, Zhou H, Webber AL, Freshwater T, Sharma MR. Chénard-Poirier M, et al. Among authors: gutierrez me. Invest New Drugs. 2024 Jun;42(3):241-251. doi: 10.1007/s10637-024-01428-0. Epub 2024 Mar 14. Invest New Drugs. 2024. PMID: 38483782 Free PMC article. Clinical Trial.
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.
Tran B, Voskoboynik M, Bendell J, Gutierrez M, Lemech C, Day D, Frentzas S, Garrido-Laguna I, Standifer N, Wang F, Ferte C, Wang Y, Das M, Carneiro BA. Tran B, et al. Among authors: gutierrez m. Immunotherapy. 2024;16(11):759-774. doi: 10.1080/1750743X.2024.2359359. Epub 2024 Sep 12. Immunotherapy. 2024. PMID: 39264730 Free PMC article. Clinical Trial.
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Ip A, Petrillo A, Della Pia A, Lee GG, Gill S, Varughese T, Zenreich J, Gutierrez M, Zhang J, Ahn J, Bharani V, Nejad AS, Pascual L, Feldman TA, Leslie LA, Goy AH. Ip A, et al. Among authors: gutierrez m. Leuk Lymphoma. 2023 Dec;64(14):2225-2235. doi: 10.1080/10428194.2023.2259528. Epub 2023 Dec 25. Leuk Lymphoma. 2023. PMID: 37740588 Free article. Clinical Trial.
3,100 results